Marques E T, Ichikawa Y, Strand M, August J T, Hart G W, Schnaar R L
Department of Pharmacology and Molecular Sciences and Department of Biological Chemistry, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA.
Glycobiology. 2001 Mar;11(3):249-59. doi: 10.1093/glycob/11.3.249.
Glycoconjugate-bound fucose, abundant in the parasite Schistosoma mansoni, has been found in the form of Fucalpha1,3GlcNAc, Fucalpha1,2Fuc, Fucalpha1,6GlcNAc, and perhaps Fucalpha1,4GlcNAc linkages. Here we quantify fucosyltransferase activities in three developmental stages of S. mansoni. Assays were performed using fluorophore-assisted carbohydrate electrophoresis with detection of radioactive fucose incorporation from GDP-[(14)C]-fucose into structurally defined acceptors. The total fucosyltransferase-specific activity in egg extracts was 50-fold higher than that in the other life stages tested (cercaria and adult worms). A fucosyltransferase was detected that transferred fucose to type-2 oligosaccharides (Galbeta1,4GlcNAc-R), both sialylated (with the sialic acid attached to the terminal Gal by alpha2,3 or 2,6 linkage) and nonsialylated. Another fucosyltransferase was identified that transferred fucose to lactose-based and type-2 fucosylated oligosaccharides, such as LNFIII (Galbeta1,4(Fucalpha1,3)GlcNAcbeta1,3Galbeta1,4Glc). A low level of fucosyltransferase that transfers fucose to no-sialylated type-1 oligosaccharides (Galbeta1,3GlcNAc-R) was also detected. These studies revealed multifucosylated products of the reactions. In addition, the effects of fucose-type iminosugars inhibitors were tested on schistosome fucosyltransferases. A new fucose-type 1-N-iminosugar was four- to sixfold more potent as an inhibitor of schistosome fucosyltransferases in vitro than was deoxyfuconojirimycin. In vivo, this novel 1-iminosugar blocked the expression of a fucosylated epitope (mAb 128C3/3 antigen) that is associated with the pathogenesis of schistosomiasis.
糖缀合物结合的岩藻糖在曼氏血吸虫中含量丰富,已发现其以Fucα1,3GlcNAc、Fucα1,2Fuc、Fucα1,6GlcNAc以及可能的Fucα1,4GlcNAc连接形式存在。在此,我们对曼氏血吸虫三个发育阶段的岩藻糖基转移酶活性进行了定量分析。采用荧光辅助碳水化合物电泳进行检测,通过检测放射性岩藻糖从GDP - [(14)C] - 岩藻糖掺入结构明确的受体中来进行分析。卵提取物中的总岩藻糖基转移酶比活性比其他测试的生命阶段(尾蚴和成虫)高50倍。检测到一种岩藻糖基转移酶,它能将岩藻糖转移至2型寡糖(Galβ1,4GlcNAc - R),包括唾液酸化的(唾液酸通过α2,3或2,6连接连接至末端Gal)和非唾液酸化的。还鉴定出另一种岩藻糖基转移酶,它能将岩藻糖转移至基于乳糖的和2型岩藻糖基化的寡糖,如LNFIII(Galβ1,4(Fucα1,3)GlcNAcβ1,3Galβ1,4Glc)。还检测到一种低水平的岩藻糖基转移酶,它能将岩藻糖转移至非唾液酸化的1型寡糖(Galβ1,3GlcNAc - R)。这些研究揭示了反应的多岩藻糖基化产物。此外,测试了岩藻糖型亚氨基糖抑制剂对血吸虫岩藻糖基转移酶的影响。一种新的岩藻糖型1 - N - 亚氨基糖在体外作为血吸虫岩藻糖基转移酶抑制剂的效力比脱氧野尻霉素高4至6倍。在体内,这种新型1 - 亚氨基糖阻断了与血吸虫病发病机制相关的岩藻糖基化表位(单克隆抗体128C3/3抗原)的表达。